Akebia Therapeutics, Inc. - COMMON STOCK (AKBA)

CUSIP: 00972D105

Q1 2023 13F Holders as of 31 Mar 2023

Holder snapshot 7 signals
Share change
-139,230
Put/Call ratio
38%
SEC-reported price per share
$0.56
Number of holders
62
Value change
-$98,488
Number of buys
22
Open additional details 1 more signal available
Number of sells
29
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
270,093,163

Security key

00972D105

Report period

Q1 2023

Institutions

62

Top holders

10

Ownership snapshot

Top reported holders of AKBA - Akebia Therapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Alerce Investment Managem...
Disclosed value leader
Alerce Investment Managem...
Comparable rows
0/15
Latest evidence
31 Dec 2022
13F 3/4/5 Highest disclosed value: $8,706,999 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Alerce Investment Management, L.P. has the largest disclosed position value at $8.71M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Alerce Investment Management, L.P.'s linked filing trail.
Disclosed position value Top 5
Alerce Investment Management, L.P. $8.71M
VANGUARD GROUP INC $6.48M
ACADIAN ASSET MANAGEMENT LLC $4.32M
BlackRock Finance, Inc. $1.69M
RENAISSANCE TECHNOLOGIES LLC $1.66M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Alerce Investment Management, L.P.
13F
Company
13F
—
denominator unverified
$8,706,999
15,090,119 shares
— 31 Dec 2022
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$6,484,828
11,238,870 shares
— 31 Dec 2022
ACADIAN ASSET MANAGEMENT LLC
13F
Company
13F
—
denominator unverified
$4,316,000
7,483,053 shares
— 31 Dec 2022
BlackRock Finance, Inc.
13F
Company
13F
—
denominator unverified
$1,686,310
2,922,545 shares
— 31 Dec 2022
RENAISSANCE TECHNOLOGIES LLC
13F
Company
13F
—
denominator unverified
$1,665,000
2,886,227 shares
— 31 Dec 2022
JACOBS LEVY EQUITY MANAGEMENT, INC
13F
Company
13F
—
denominator unverified
$1,162,521
2,014,767 shares
— 31 Dec 2022
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2023

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
62
Shares
51,839,170
Rows available
62
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2023 vs Q1 2023 Across Filers

Q1 2023 holders
62
Q1 2023 holders
62
Holder diff
0
Investor Q1 2023 Shares Q1 2023 Shares Share Diff Share Chg % Q1 2023 value Q1 2023 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .